Abstract
A 61-year-old white man presented with a stenosing tumour of the right colon and a large hepatic metastasis measuring 90 mm in its largest diameter, judged not suitable for immediate resection. He underwent right hemicolectomy and received 12 cycles of treatment with 5-fluorouracil/leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) plus bevacizumab. According to Response Evaluation Criteria in Solid Tumors (RECIST criteria), he achieved a partial response that allowed a secondary radical hepatic resection. Pathologic examination of the liver specimen showed the absence of residual tumour cells: a pathologic complete response (pCR) was achieved. In this case, an intensive up-front treatment (i.e. the combination of FOLFOXIRI plus bevacizumab) produced the pCR of a liver metastasis from colorectal cancer despite its initial large dimension while confirming the possible discrepancy between radiologic assessment and pathological findings.
Keywords: Metastatic colorectal cancer, liver resection, preoperative chemotherapy, bevacizumab, FOLFOXIRI, complete pathologic response.
Clinical Cancer Drugs
Title:Case-Report: Folfoxiri Plus Bevacizumab in “Poor-Risk” Liver-Only Metastatic Colorectal Cancer: Case Report and State-of-the-Art
Volume: 1
Author(s): Lisa Salvatore, Fotios Loupakis, Andrea Ciarlo, Chiara Cremolini, Camilla Comin, Marta Schirripa, Luca Messerini, Federica Marmorino, Carlotta Antoniotti and Alfredo Falcone
Affiliation:
Keywords: Metastatic colorectal cancer, liver resection, preoperative chemotherapy, bevacizumab, FOLFOXIRI, complete pathologic response.
Abstract: A 61-year-old white man presented with a stenosing tumour of the right colon and a large hepatic metastasis measuring 90 mm in its largest diameter, judged not suitable for immediate resection. He underwent right hemicolectomy and received 12 cycles of treatment with 5-fluorouracil/leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) plus bevacizumab. According to Response Evaluation Criteria in Solid Tumors (RECIST criteria), he achieved a partial response that allowed a secondary radical hepatic resection. Pathologic examination of the liver specimen showed the absence of residual tumour cells: a pathologic complete response (pCR) was achieved. In this case, an intensive up-front treatment (i.e. the combination of FOLFOXIRI plus bevacizumab) produced the pCR of a liver metastasis from colorectal cancer despite its initial large dimension while confirming the possible discrepancy between radiologic assessment and pathological findings.
Export Options
About this article
Cite this article as:
Salvatore Lisa, Loupakis Fotios, Ciarlo Andrea, Cremolini Chiara, Comin Camilla, Schirripa Marta, Messerini Luca, Marmorino Federica, Antoniotti Carlotta and Falcone Alfredo, Case-Report: Folfoxiri Plus Bevacizumab in “Poor-Risk” Liver-Only Metastatic Colorectal Cancer: Case Report and State-of-the-Art, Clinical Cancer Drugs 2014; 1 (1) . https://dx.doi.org/10.2174/2212697X0101131204152941
DOI https://dx.doi.org/10.2174/2212697X0101131204152941 |
Print ISSN 2212-697X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-6988 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice
Current Gene Therapy Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Chemopreventive Properties of Tolfenamic Acid: A Mechanistic Review
Current Medicinal Chemistry Target Identification of Grape Seed Extract in Colorectal Cancer Using Drug Affinity Responsive Target Stability (DARTS) Technique: Role of Endoplasmic Reticulum Stress Response Proteins
Current Cancer Drug Targets Microspheres and Microcapsules for Protein Delivery: Strategies of Drug Activity Retention
Current Pharmaceutical Design Biological Rationales and Clinical Applications of Temperature Controlled Hyperthermia - Implications for Multimodal Cancer Treatments
Current Medicinal Chemistry Tumor-Specific Delivery of Histidine-Rich Glycoprotein Suppresses Tumor Growth and Metastasis by Anti-angiogenesis and Vessel Normalization
Current Gene Therapy Gut Epithelial Lining Makes the First Move
Current Immunology Reviews (Discontinued) Anti-Cancer Drug Discovery: Structure, Function and Novel Strategy – (Part-I)
Current Topics in Medicinal Chemistry The Development of Targeted Therapies for Hepatocellular Cancer
Current Pharmaceutical Design Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance
Anti-Cancer Agents in Medicinal Chemistry Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers Drugs Made of RNA: Development and Application of Engineered RNAs for Gene Therapy
Mini-Reviews in Medicinal Chemistry Epigenetic Regulation of Epithelial-Mesenchymal Transition by Hypoxia in Cancer: Targets and Therapy
Current Pharmaceutical Design Before and After Preeclampsia: What Biomarkers are there?
Current Women`s Health Reviews Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets Towards the Management of Inflammation: Recent Developments of mPGES-1 Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) Editorial
Current Medicinal Chemistry Hereditary Papillary Renal Carcinoma Type I
Current Molecular Medicine Meet Our Editorial Board Member
Recent Patents on Drug Delivery & Formulation